September 11th 2025
Oxford’s Prof Katrina Lythgoe and Mahan Ghafari, DPhil, report ONS-CIS data on 576 persistent UK infections with rapid within-host evolution and rare transmission after one month.
September 10th 2025
William Hanage, PhD, discusses viral evolution, transmission risk, and clinical implications for immunocompromised patients.
September 3rd 2025
Single-center randomized trial shows lower infection rates and extended time to SARS-CoV-2 infection, though larger studies are needed to confirm findings.
September 2nd 2025
Supported by phase 3 SCORPIO-PEP trial data, ensitrelvir could become the first oral therapy to prevent COVID-19 following exposure, with an FDA decision due June 16, 2026.
August 29th 2025
Spikevax and mNEXSPIKE authorized for older adults and high-risk individuals; experts emphasize protection against severe COVID-19 outcomes.
Thomas M. File, Jr., MD: COVID-19 Requires a Unified Approach
March 5th 2020In addition to providing important expertise into the management of this infection, our role in educating the public—in many cases providing an important perspective when fears tend to run high—is also essential.
Read More
259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831